Mark Daniel Benson, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proteomics | 11 | 2023 | 3912 | 1.230 |
Why?
|
| Aptamers, Nucleotide | 4 | 2020 | 163 | 1.020 |
Why?
|
| Blood Proteins | 7 | 2024 | 1191 | 0.960 |
Why?
|
| Metabolomics | 5 | 2023 | 1674 | 0.690 |
Why?
|
| SELEX Aptamer Technique | 1 | 2019 | 19 | 0.680 |
Why?
|
| High-Throughput Screening Assays | 3 | 2020 | 942 | 0.500 |
Why?
|
| Coronary Artery Disease | 3 | 2022 | 6568 | 0.360 |
Why?
|
| Proteome | 4 | 2022 | 1890 | 0.360 |
Why?
|
| Peripheral Arterial Disease | 1 | 2022 | 1304 | 0.360 |
Why?
|
| Genome-Wide Association Study | 8 | 2024 | 12795 | 0.350 |
Why?
|
| Cardiovascular Diseases | 5 | 2022 | 15662 | 0.320 |
Why?
|
| Cardiovascular System | 1 | 2016 | 841 | 0.310 |
Why?
|
| Genetic Variation | 2 | 2020 | 6611 | 0.260 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2021 | 856 | 0.250 |
Why?
|
| Atherosclerosis | 1 | 2021 | 3433 | 0.240 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 4568 | 0.230 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 2257 | 0.220 |
Why?
|
| Quantitative Trait Loci | 3 | 2024 | 2131 | 0.210 |
Why?
|
| Chemokine CX3CL1 | 1 | 2021 | 62 | 0.190 |
Why?
|
| Echocardiography | 2 | 2021 | 5047 | 0.150 |
Why?
|
| Teaching Rounds | 1 | 2022 | 282 | 0.150 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2017 | 1334 | 0.150 |
Why?
|
| Heredity | 1 | 2017 | 149 | 0.140 |
Why?
|
| Proteoglycans | 1 | 2020 | 809 | 0.140 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 3251 | 0.140 |
Why?
|
| Coronary Disease | 2 | 2022 | 5919 | 0.140 |
Why?
|
| Hep G2 Cells | 1 | 2017 | 378 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 724 | 0.120 |
Why?
|
| Risk Factors | 8 | 2023 | 74944 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 12252 | 0.110 |
Why?
|
| Adipocytes | 1 | 2019 | 1197 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2202 | 0.100 |
Why?
|
| Carotid Artery Diseases | 1 | 2018 | 879 | 0.100 |
Why?
|
| Heart Failure | 3 | 2021 | 11879 | 0.100 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2017 | 1040 | 0.100 |
Why?
|
| Aptamers, Peptide | 2 | 2022 | 28 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 1461 | 0.100 |
Why?
|
| Humans | 28 | 2024 | 768166 | 0.100 |
Why?
|
| Databases, Genetic | 1 | 2017 | 1758 | 0.090 |
Why?
|
| Phenotype | 5 | 2022 | 16726 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2945 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 15454 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2022 | 6430 | 0.070 |
Why?
|
| Myocardium | 2 | 2017 | 4788 | 0.070 |
Why?
|
| Longitudinal Studies | 5 | 2022 | 14783 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2024 | 4887 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 20227 | 0.070 |
Why?
|
| Middle Aged | 12 | 2024 | 223492 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 16045 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 4793 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2019 | 3986 | 0.060 |
Why?
|
| Incidence | 5 | 2022 | 21538 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2022 | 24315 | 0.060 |
Why?
|
| Kidney | 1 | 2020 | 7064 | 0.060 |
Why?
|
| Graft Rejection | 1 | 2017 | 4492 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5889 | 0.060 |
Why?
|
| Heart Transplantation | 1 | 2017 | 3301 | 0.060 |
Why?
|
| Male | 13 | 2024 | 364719 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2022 | 1197 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 4206 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2023 | 23645 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 26379 | 0.050 |
Why?
|
| Animals | 4 | 2023 | 169246 | 0.050 |
Why?
|
| Cholesterol, LDL | 2 | 2022 | 2403 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 9538 | 0.050 |
Why?
|
| Homoarginine | 1 | 2021 | 9 | 0.050 |
Why?
|
| Orotic Acid | 1 | 2021 | 24 | 0.050 |
Why?
|
| Mice | 3 | 2023 | 82029 | 0.050 |
Why?
|
| Spermine | 1 | 2021 | 70 | 0.050 |
Why?
|
| Uridine | 1 | 2021 | 135 | 0.040 |
Why?
|
| Polyamines | 1 | 2021 | 133 | 0.040 |
Why?
|
| Aged | 7 | 2024 | 171504 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 5176 | 0.040 |
Why?
|
| Dipeptidases | 1 | 2019 | 38 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2019 | 56 | 0.040 |
Why?
|
| Female | 12 | 2024 | 397192 | 0.040 |
Why?
|
| Cystatin C | 1 | 2021 | 272 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 18065 | 0.040 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2019 | 85 | 0.040 |
Why?
|
| Ribonucleotides | 1 | 2019 | 114 | 0.040 |
Why?
|
| Proline | 1 | 2021 | 455 | 0.040 |
Why?
|
| Follistatin | 1 | 2019 | 138 | 0.040 |
Why?
|
| Norway | 1 | 2020 | 501 | 0.040 |
Why?
|
| 5'-Nucleotidase | 1 | 2019 | 164 | 0.040 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2021 | 393 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 684 | 0.040 |
Why?
|
| Kidney Glomerulus | 1 | 2020 | 570 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2018 | 183 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 472 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2019 | 558 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2019 | 617 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 486 | 0.030 |
Why?
|
| Lymphokines | 1 | 2019 | 924 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 12543 | 0.030 |
Why?
|
| Adult | 8 | 2024 | 223646 | 0.030 |
Why?
|
| Podocytes | 1 | 2020 | 403 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2019 | 596 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 65371 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 11519 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2018 | 594 | 0.030 |
Why?
|
| Metabolome | 1 | 2022 | 1009 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 905 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2017 | 255 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2022 | 1188 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 2016 | 351 | 0.030 |
Why?
|
| Antibodies | 1 | 2022 | 2421 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2016 | 996 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2020 | 1281 | 0.030 |
Why?
|
| Collagen | 1 | 2021 | 2643 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2021 | 1751 | 0.030 |
Why?
|
| Cholesterol | 1 | 2021 | 2914 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2021 | 2146 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 2227 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2021 | 22291 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 2909 | 0.020 |
Why?
|
| United States | 3 | 2022 | 73039 | 0.020 |
Why?
|
| Risk | 1 | 2021 | 9613 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5151 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2021 | 3048 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2022 | 41754 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 4249 | 0.020 |
Why?
|
| Sex Factors | 1 | 2021 | 10632 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8890 | 0.020 |
Why?
|
| Acute Disease | 1 | 2017 | 7243 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2021 | 5622 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5315 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2018 | 9669 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 6793 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 15597 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 54926 | 0.010 |
Why?
|
| Genotype | 1 | 2018 | 13045 | 0.010 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 2194 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 22379 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14729 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 13090 | 0.010 |
Why?
|
| Hypertension | 1 | 2020 | 8616 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39348 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 30010 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40218 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 59629 | 0.010 |
Why?
|